Long-term treatment of chronic schizophrenia with risperidone: A study with plasma levels

European Psychiatry

Volumn 16, Issue 1, 2001, Pages 57-63

  Mauri, M C ^a   Laini, V ^a   Boscati, L ^a   Rudelli, R ^a   Salvi, V ^a   Orlandi, R ^b   Papa, P ^b  

^a UNIVERSITY OF MILAN   (Italy)

^b FONDAZIONE IRCCS POLICLINICO SAN MATTEO   (Italy)

Author keywords

9 hydroxy risperidone; Pharmacokinelics; Plasma levels; Risperidone; Schizophrenia

Indexed keywords

PALIPERIDONE; RISPERIDONE;

ADULT; ANTICHOLINERGIC EFFECT; ARTICLE; BODY WEIGHT; CLINICAL ARTICLE; DOSE CALCULATION; DRUG BLOOD LEVEL; EXTRAPYRAMIDAL SYMPTOM; FEMALE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; LONG TERM CARE; MALE; OUTPATIENT; PRIORITY JOURNAL; RATING SCALE; SCHIZOPHRENIA;

EID: 0035102075     PISSN: 09249338     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0924-9338(00)00536-8     Document Type: Article

References (38)

1. Risperidone clinical efficacy: Role of the metabolite 9-hydroxy-risperidone
2. Risperidone versus clozapine in treatment-resistant chronic schizophrenia: A randomized double-blind study
3. Risperidone in the treatment of negative symptoms of schizophrenia: A metaanalysis
4. A Canadian multicenter placebocontrolled study of fixed doses of risperidone and haloperidol in the treatment of chronic schizophrenic patients
5. Risperidone versus haloperidol in the treatment of chronic schizophrenic inpatients: A multicentre doubleblind comparative study
6. Rehospitalization rates of patients recently discharged on a regimen of risperidone or clozapine
7. Commentary: The strategy and value of neuroleptic drug monitoring
8. Efficacy and tolerability of risperidone in drug-naive schizophrenic and schizoaffective patients
9. Pharmacological profile of risperidone
10. Drug treatment of schizophrenia in the 1990s. Achievements and future possibilities in optimising outcomes
11. Risperidone. A pharmacoeconomic review of its use in schizophrenia
12. Pilot dinical investigation of risperidone in the treatment of psychotic patients
13. Risperidone. A review of its pharmacology and therapeutic potential in the treatment of schizophrenia
14. The pharmacokinetics of risperidone in humans: A summary
15. The Positive and Negative Syndrome Scale (PANSS) for Schizophrenia
16. Efficacy and safety of risperidone in the long-term treatment of patients with schizophrenia
17. Alteration in the recommended dosing schedule for risperidone
18. Absorption, metabolism and excretion of risperidone in humans
19. Risperidone in the treatment of schizophrenia
20. Risperidone and 9OH-risperidone plasma levels in schizophrenic patents
21. Long-term treatment of chronic schizophrenic patients with risperidone
22. The prevalence of acute extrapyramidal signs and symptoms in patients treated with clozapine, risperidone and conventional antipsychotics
23. Long-term treatment of chronic schizophrenia with risperidone: An open-label multicenter study of 386 patients
24. Therapeutic equivalence of risperidone given Once daily and twice daily in patients with schizophrenia
25. Suggested minimal effective dose of risperidone based on PETmeasured D2 and 5HT2A receptor occupancy in schizophrenic patients
26. Brief Psychiatric Rating Scale
27. Therapeutic drug monitoring of risperidone and 9-hydroxy-risperidone in serum with solid phase extraction and high-performance liquid cromatography
28. Guidelines for the practical use of risperidone
29. Clinical considerations in the use of risperidone
30. A rating scale for Extrapyramidal Side Effects
31. Influence of age, renal and liver impairment on the pharmacokinetics of risperidone in man
32. The regional brain distribution of risperidone and its active metabolite 9-hydroxyrisperidone in the rat
33. Clinical pharmacokinetics of risperidone
34. Atypical antipsychotic drugs and long-term outcome in schizophrenia
35. Risperidone in treatment-refractory schizophrenia
36. Determination of risperidone and 9-hydroxy risperidone in plasma, urine and animal tissues by high performance liquid chromatography